Congratulations to Ayesha Singh who gave an absolutely flawless presentation on our work to identify predictors of angina relief following revascularization in the ISCHEMIA trial. #ACC2024

If PCI as a 'therapy' for stable ischemic heart disease is controversial, its role as a 'prevention' for vulnerable plaques is even more controversial.

In a few weeks, at ACC.24, the PREVENT investigators will present the results of a multicenter, open-label, randomized…

Another example of conflating association with causation. Almost any obs study of exercise will be positive b/c people that exercise are usually healthier to begin with. And a large sample size doesn't prevent cofounding. NPR Allison Aubrey Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦

npr.org/sections/healt…

Honored to have been invited to participate with Ayesha Singh by EuroIntervention in a debate on stenting of vulnerable plaque. Bottom line: please don't. eurointervention.pcronline.com/article/prophy…

Why so much overuse of hydralazine /isosorbide dinitrate as GDMT in HFrEF?
VHEFT 1-no sig diff from placebo in pep ( secondary outcomes favored H/I)
VHEFT2-H/I inferior to enalapril
AHEFT- H/I beneficial when added to GDMT (not instead of it)

Excited to have Keck School of Medicine of USC superstar internal medicine resident, Ayesha Singh, present our studies on predictors of freedom from angina in the ISCHEMIA trial at American College of Cardiology.

Excited to have USC superstar internal medicine resident, Ayesha Singh, present our study on predictors of freedom from angina in the ISCHEMIA trial at American College of Cardiology.

On a related topic, how does one accept the results of ISCHEMIA and still find value in FFR?

Harlan. Ugh.

Only in LA

A Palestinian man thanks Hamas for making sure that all the Palestinian people who used to commute into Israel to work will now be unemployed.

He also thanks Hamas for making sure Palestinian kids will no longer receive surgeries in Israel

Great job!

instagram.com/p/Czj6_cnvQMv/…

When the extent of Hamas’ takeover of the Shifa Hospital becomes clear, a lot of international and UN agencies are going to look very, very silly as people rightfully ask: You should have known—why didn’t you say anything?

Does anybody else find it amusing that there are zero complaints about ORBITA 2 being too small or with too much single vessel disease or with too short a follow-up like there were with ORBITA1? What could be the difference?

If only there were a network of tunnels to protect civilians and hospitals.
The Tunnels of Gaza nytimes.com/interactive/20…

If only there were a system of underground tunnels that civilians and hospitals could use to protect themselves.
The Tunnels of Gaza nytimes.com/interactive/20…

medscape.com/viewarticle/99…

instagram.com/reel/CyZiomNMu…